DOYLESTOWN, PA - August 1, 2005 - The Quigley Corporation (Nasdaq: QGLY),
the leading developer
and marketer of diversified health products, today announced that its wholly-owned Quigley Pharma
(Ethical Pharmaceuticals) subsidiary has obtained results from its continued pre-clinical research on
QR440, botanical broad-spectrum anti-inflammatory compound, which show that QR440 may have
disease-modifying potential.
In Vitro studies conducted at MD Biosciences supports the conclusion of previous animal study findings
showing that QR440 can inhibit inflammatory cell recruitment and delayed type hypersensitivity (DTH).
The current study suggests that the mechanism of action effecting cell recruitment and DTH is in fact the
inhibition of a broad range of cytokine's including (IL-2, IL-5, IL-12). In particular, these recent studies
demonstrate that the compound inhibits IFNy and TNFa at 24 and 48 hours at low doses. The inhibition
of TNFa is especially relevant in determining disease-modifying activity.
The MD Biosciences Study MDQP1, "Evaluation of QR440 In The In Vitro Cell Stimulation Model,"
was designed to determine the effect of compound QR440 on the expression of cytokines resulting from
stimulation of a culture made from a lymph node single cell suspension.
The Quigley Corporation's President and CEO Guy Quigley stated, "A Natural compound that could
reduce inflammation and its subsequent symptoms, as well as function to modify disease, would meet a
significant unmet need. We look forward to further development and testing of this unique compound."
According to the Company, although these results are encouraging, future clinical safety and efficacy
research will be needed to determine if QR440 is to become the first prescription botanical Non-Steroidal
Anti-Inflammatory (NSAID) and/or Disease Modifying Anti-Rheumatic Drug (DMARD).
The Quigley Corporation
The Quigley Corporation is the leading developer and marketer of diversified health products. The
company's proven success in launching first-in-category health solutions supports the Pharma subsidiary
in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes
and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any
other regulatory agency will grant an IND or take any other action to allow the aforementioned compound
to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is
safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and
marketer of diversified health products including the COLD-EEZEŽ family of patented zinc gluconate
glycine (ZIGGTM) lozenges and sugar free tablets. In October of 2004, The Company, through its wholly
owned subsidiary, Quigley Manufacturing, Inc. acquired two FDA approved facilities to manufacture its
COLD- EEZEŽ branded lozenges. InnerLight Inc., a wholly owned subsidiary, was formed in December
2000 for the purpose of introducing new products to the marketplace through a network of independent
distributors. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma
Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a
line of naturally derived patented prescription drugs. The Quigley Corporation's customers include
leading national wholesalers and distributors, as well as independent and chain food, drug and mass
merchandise stores and pharmacies.
Certain statements in this press release are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and
other factors that may cause the company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the forward-looking statement.
Factors that impact such forward-looking statements include, among others, changes in worldwide
general economic conditions, changes in interest rates, government regulations, and worldwide
competition.
